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Abstract Anticoagulant prophylaxis for preventing
venous thromboembolism (VTE) isa worldwide established
procedure in hip and knee replacement surgery, as well as in
the treatment of femoral neck fractures (FNF). Different
guidelines are available in the literature, with quite different
recommendations.Noneofthemisamultidisciplinaryeffort
as the one presented. The Italian Society for Studies on
HaemostasisandThrombosis(SISET),theItalian Societyof
Orthopaedics and Traumatology (SIOT), the association of
Orthopaedists and Traumatologists of Italian Hospitals
(OTODI), together with the Italian Society of Anesthesia,
Analgesia, Resuscitation, and Intensive Care (SIAARTI)
have set down easy and quick suggestions for VTE pro-
phylaxisinhipandkneesurgeryaswellasinFNFtreatment.
This inter-society consensus statement aims at simplifying
thegradingsystemreportedintheliterature,anditsgoalisto
beneﬁt its clinical application. Special focus is given to
fragile patients, those with high bleeding risk, and those
receiving chronic antiplatelet (APT) and vitamin K antago-
nists treatment. A special chapter is dedicated to regional
anaesthesia and VTE prophylaxis.
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Venous thromboembolism (VTE) represents a problem of
relevant clinical and social impact. Recent data indicate an
incidence of VTE of approximately 900,000 cases per year
in the USA and of approximately 770,000 in Europe; in
addition, pulmonary embolism (PE) is the direct cause of
almost 10% of in-hospital deaths [1].
Anticoagulant prophylaxis for preventing VTE is a well-
established procedure in hip (HR) and knee (KR) replace-
ment surgery and in treating femoral neck fractures (FNF).
Several meta-analyses indicate that in patients undergoing
thiskindofprophylactictreatment,animportantreductionin
symptomaticVTEisseen,withnorelevantincreaseinmajor
bleeding events [1–5]. These observations led the American
College of Chest Physicians to generate universally recog-
nized grade Ia recommendations on the need to initiate
prophylaxis before all HR surgical interventions and to
prolong treatment during the following 5 weeks. At present,
pharmacologicaland/ormechanicalprophylaxis isstartedin
all cases of major orthopedic surgery (MOS), including
elective HR and KR, and FNF surgery, as well as in several
other cases of fracture (high-impact trauma, multiple frac-
tures, multiple trauma) [1].
The Italian Society for Studies on Haemostasis and
Thrombosis (SISET) has been focussing its research efforts
on this topic for many years [2, 3]. When the need to for-
mulate practical recommendations arose in the world of
orthopedics and traumatology, the Italian Society of Ortho-
paedics and Traumatology (SIOT) and the association of
Orthopaedists and Traumatologists of Italian Hospitals
(OTODI) identiﬁed SISET and the Italian Society of Anes-
thesia, Analgesia, Resuscitation and Intensive Care (SIA-
ARTI) as their natural counterparts. This intersociety
consensus statement aims at simplifying the grading
system reported in the literature, and its goal is to
improve its clinical application. For this reason, we
believed that there was no need to deﬁne the strength of
recommendations provided, as national and international
dedicated guidelines already exist [1–5]. This statement
is therefore addressed to the Italian scientiﬁc community
and institutions with the aim of attaining good clinical
practice in the profession.
The present statement will be published in the Journals
of the different Societies participating in this consensus.
Purpose
Four purposes have been identiﬁed:
1. Keeping patients as safe as possible concerning the
possibility of a thromboembolic event as a potential
sequela in case of HR, KR, or FNF surgery in adults.
2. Reducing the possible complications linked to anti-
thrombotic prophylaxis following HR, KR, or FNF
surgery as much as possible.
3. Providing all specialists involved with unequivocal
indications on the types of antithrombotic prophylaxis
to be followed, in keeping with data reported in the
national and international literature and with the laws
in force in Italy.
4. Supplying useful suggestions on daily clinical practice
in all situations in which no clear evidence is provided.
Patients
Patients were subdivided into three groups:
– Patients at high risk of VTE;
– Patients at high risk of bleeding;
– Particular or ‘‘fragile’’ patients requiring individualized
treatment.
Patients at high risk of VTE
All patients undergoing HR, KR, or FNF surgery are at
high risk of VTE and must follow an antithrombotic
prophylaxis protocol. In-depth hematological and instru-
mental screening in quest of additional risk factors for
thromboembolism is not believed to be essential, as
knowledge of these factors would not alter the
Table 1 Patients at high risk of bleeding and patients who need careful evaluation for possible risk of bleeding
Patients at high risk of bleeding Patients to be carefully evaluated for possible risk of bleeding
Prolonged PT (INR[1.5) Prolonged APTT (except antiphospholipid antibody syndrome)
Thrombocytopenia\50,000/ll
Known bleeding diathesis Severe CRF (creatinine clearance\30 ml/min)
Chronic liver disease with prior bleeding episodes Family or personal history of major bleeding
Multiple trauma (ISS C 15) Concomitant use of drugs affecting hemostasis
(e.g., antiplatelet drugs, anti-inﬂammatory drugs)
PT prothrombin time, INR International normalized ratio, ISS injury severity score, APTT antiplatelet treatment, CRF chronic renal failure
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123prophylactic strategies. An exception is made for patients
with past episodes of deep vein thrombosis (DVT) and/or
pulmonary embolism, who require an individualized
preventive/curative approach.
Patients at high risk of bleeding
Patients at high risk of bleeding are described in Table 1.
Fragile patients
Fragile patients requiring individualized treatment are
those who present with:
– Body weight\50 kg
– Age[75 years
– Moderate chronic renal failure (CRF) (creatinine
clearance 30–50 ml/min)
The creation of a personalized, shared folder for
thrombotic and hemorrhagic risk assessment and initiation
of adequate thromboprophylaxis is suggested in all hospital
settings. Furthermore, we recommend that the creation of
this document be suggested by all administrations involved
(hospital directorate, local health authority, regional
administration, etc.).
Type of prophylaxis
Pharmacological LMWH, FON, NOA, VKA, UH
Mechanical Active (IPC, VFP)
Passive (GCS)
Combined Pharmacological ? mechanical
LMWH low-molecular-weight heparin, FON fondaparinux, NOA new
oral anticoagulants, UH unfractionated heparin, VKA vitamin K
antagonists, VFP venous foot pump, IPC intermittent pneumatic
compression, GCS graduated compression stockings
Pharmacological prophylaxis
– Pharmacological prophylaxis is based on low-molecu-
lar-weight heparin (LMWH), fondaparinux (FON), and
new oral anticoagulants (NOA).
– Aspirin must not be used for VTE prophylaxis, as
indicated by its label and by current guidelines.
– Unfractionated heparin (UH) must not be used consid-
ering that its efﬁcacy is lower than that of LMWH, it
has a short half-life, and it more frequently induces
thrombocytopenia.
– Vitamin K antagonists (VKA) should not be adminis-
tered because they are difﬁcult to manage and maintain
within a range of therapeutic anticoagulation [Interna-
tional normalized ratio (INR) ranging between 2 and 3].
Exceptions are possible but must be evaluated on an indi-
vidualized basis with the consultant cardiologist or an
expert in hemostasis and thrombosis.
Low-molecular-weight heparin (LMWH)
Concerning HR and KR, no differences in efﬁcacy and
safety have been reported between LMWH preoperative
and postoperative ﬁrst administration (Table 2)[ 6, 7].
LMWH labels in Italy, however, require a preoperative ﬁrst
administration except for bemiparin and dalteparin (for the
latter only in hip surgery).
Fondaparinux (FON)
Fondaparinux has proved to be effective and safe in VTE
prevention in HR, KR, and FNF (Table 3)[ 8]. In particular,
FON has been reported to be more effective than LMWH
(only demonstrated by decrease in phlebography-proven
asymptomatic DVT) with modest, although statistically
Table 2 Dosage and time of administration of low-molecular-weight heparin (LMHW) available in Italy
Active
principle
Brand name Dosage and time of administration
Enoxaparin Clexane
 4,000 IU 12 h before surgery, then 4,000 IU/day
Nadroparin Fraxiparine

Seleparin

38 IU/kg 12 h before surgery and 12 h after, 38 IU/kg every 24 h during the 3 days following surgery,
thereafter increasing the dose to 57 IU/kg/day
Dalteparin Fragmin
 5,000 IU 8–12 h before surgery, then 5,000 IU/day. Alternatively 2 h, 500 IU 1–2 before surgery
a and
2,500 IU 8–12 h after, thereafter either 5,000 IU/day or (only in hip surgery) 2,500 IU 4–8 h after surgery
then 5,000 IU/day
Bemiparin Ivor
 3,500 IU 6 h after surgery, then 3,500 IU/day. Alternatively 3,500 IU 2 h before surgery
a, then 3,500 IU/day
Parnaparin Fluxum
 0.4 ml (4,250 anti-Xa IU) 12 h before surgery, then 0.4 ml (4,250 anti-Xa IU)/day
Reviparin Clivarin
 0.4 ml (4,200 anti-Xa IU) 12 h before surgery, then 0.4 ml (4,200 anti-Xa IU)/day
a Although reported by the product label, this type of prophylaxis is not recommended
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123signiﬁcant, increase in bleeding and need for transfusions
(with no related increase in fatal hemorrhage, in critical
organs, or need for reintervention).
New oral anticoagulants (NOA)
New oral anticoagulants (dabigatran and rivaroxaban) have
proved to be effective and safe in VTE prevention in HR
and KR (Table 4)[ 11–16]. On the other hand, no direct
comparison has ever been made between the two drugs,
allowing for a deﬁnite conﬁrmation of any different efﬁ-
cacy and safety. There is no evidence in the literature
concerning the use of NOA in patients undergoing FNF
surgery and concerning prolonged prophylaxis after KR;
furthermore, experience in fragile patients is limited.
Although these drugs do not require laboratory monitoring,
they have been shown to prolong PT and APTT.
Mechanical prophylaxis
Mechanical prophylaxis is based on the use of graduated
compression stockings (GCS) and on intermittent pneu-
matic compression (IPC) devices [17]. GCS (thigh-to-foot
or knee-to-foot) increase the effectiveness of pharmaco-
logical prophylaxis, must be used until recovery of good
mobility with autonomous de-ambulation (best if used on
both legs), must be correctly positioned avoiding the
‘‘tourniquet effect,’’ and must not be used in the presence
of peripheral arterial disease or diabetic neuropathy. IPC
devices (either sural or plantar) have a high efﬁcacy and
enhance the action of anticoagulant drugs, but there is a
low compliance by nurses and patients as concerns their
management.
When should prophylaxis be started?
Patients with femoral neck fracture (FNF)
Selection and initiation of the prophylactic treatment to be
followed strongly depend on the adopted schedule:
– If surgery is performed on an emergency basis (within
24 h), LMWH may be used (starting 12 h before or
12 h after) or, alternatively, FON (starting at least 6 h
after the end of the intervention and, in any case, within
24 h).
– If surgery is postponed, LMWH must be administered
early. In this case, there is no information available on
the possibility of initiating FON 6–8 h after the end of
the intervention, thus producing a shift between the two
anticoagulant drugs. At present, no recommendation
can be made on this subject.
– NOA must not be used, as no study pertaining to FNF
has been published.
Table 3 Dosage and time of administration of Fondaparinux
Active principle Brand name Dosage and time of administration
Fondaparinux ARIXTRA
 2.5 mg at least 6 h after surgery, then 2.5 mg/day
a
If creatinine clearance 20–50 ml/min 1.5 mg
b
a In agreement with the latest edition of the American College of Chest Physicians (ACCP) guidelines [1], initiation may be postponed up to
24 h after the end of the intervention [9], although this has not been included in the label as yet
b According to the recent guidelines of the European Society of Anaesthesiology [10], FON is contraindicated if creatinine clearance\30 ml/
min
Table 4 Dosage and time of administration of available new oral anticoagulants (NOA)
Active principle Brand name Dosage and time of administration
Dabigatran
a
(antifactor IIa)
Pradaxa
 110 mg 1–4 h after surgery, then 220 mg/day
If age[75 years or creatinine clearance 30–50 ml/min
or amiodarone intake, 75 mg 1–4 h after surgery, then 150 mg/day
Rivaroxaban
b
(antifactor Xa)
Xarelto
 10 mg 6–10 h after surgery, then 10 mg/day
a Dabigatran has proved not to be inferior to low-molecular-weight heparin (LMWH) both in terms of efﬁcacy and safety. As concerns
dabigatran, in the literature, there is no information available on patients undergoing regional anaesthesia [11, 12]
b Rivaroxaban has shown to have greater efﬁcacy than LMWH, with overlapping safety [13–16]. An analysis performed after publication of
rivaroxaban registration study conﬁrmed its safety in patients undergoing neuraxial anesthesia
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replacement
In the literature, no signiﬁcant difference in efﬁcacy and
safety has been reported between preoperative and post-
operative initiation of LMWH in HR and KR [1, 6, 7].
Consequently, the choice must be based on evidence
reported in published studies as well as on what is indicated
on LMWH labels, which in Italy require initiation of pro-
phylaxis 12 h before surgery, except for dalteparin and
bemiparin (Table 2). Both FON and NOA must always be
started postoperatively (Tables 3, 4).
How long should pharmacological prophylaxis last?
Concerning the duration of pharmacological prophylactic
treatment, if LMWH is used, therapy should last a mini-
mum of 10 days in all patients, with a strong recommen-
dation to protract prophylaxis for 35 days after HR and
FNF surgery and the suggestion – with a lower level of
evidence – to protract treatment similarly in patients
undergoing KR surgery [1, 18]. Regardless, in Italy, it is
standard procedure to protract prophylaxis for 35 days
even after KR surgery. This approach is also suggested for
FON therapy. As far as NOA are concerned, indications on
duration of treatment derive from registration studies and
are reported on the labels of dabigatran and rivaroxaban:
– With dabigatran, duration is 4–5 weeks in HR and
10 days in KR surgery;
– With rivaroxaban, duration is 5 weeks in HR and
2 weeks in KR surgery.
The safety of 5-week treatment with NOA has been
proven in HR studies, which suggest the reliability and
feasibility of this prophylaxis duration after KR as well.
Lastly, it must be remembered that further protraction of
prophylaxis (longer than suggested duration) has to be
addressed in patients who, for different reasons (prolonged
recumbence, additional risk factors), are at risk of devel-
oping VTE complications for a longer period than usual.
Anesthesia techniques and initiation of pharmacological
prophylaxis
No particular problem is identiﬁed in relation to general
anesthesia (GA). On the other hand, regarding regional
anesthesia (RA), timing must be carefully respected with
epidural or intrathecal anesthesia, whereas there are no
contraindications in perineural block [19, 20]. It is widely
acceptedthatRAreducestheriskofVTEandthatthecorrect
timing (prophylaxis/RA administration and, if present,
catheter removal) is crucial to prevent complications.
Actually, all anticoagulants used in VTE prevention in HR,
KR, and FNF are closely related to the risk of developing
epidural hematoma. In particular, upon removal of the epi-
duralcatheter,drugeffectiveness,half-life(T1/2),andtimeto
maximum concentration (Tmax) must be assessed: as a gen-
eral rule, the recommendation is made to wait at least 2 half-
lives before removal, resuming pharmacological prophy-
laxis after 8 h (period required for clot formation) minus
Tmax.
To simplify:
LMWH and RA [19, 20]
T1/2:4h
Tmax:4h
Last administration before catheter removal: at least
12 h.
First administration after catheter removal: at least after
6–8 h.
If LMWH is administered twice daily, either at the
prophylactic or therapeutic dosage, 24 h must pass after
catheter removal before proceeding with the following
dose.
If traumatic puncture, consider the possibility of initi-
ating prophylaxis after 24 h.
FON and RA [21]
T1/2:1 7h
Tmax:1h
If FON is administered at the therapeutic dosage, no
central block must be performed.
Last administration before catheter removal: at least
36 h.
First administration after catheter removal: at least after
12 h.
If traumatic puncture, consider the possibility of initi-
ating prophylaxis after 24 h.
NOA and RA [10]
As concerns the relationship between NOA and RA,
there is no information available (randomized clinical
studies) concerning timing and method of use; therefore,
refer to what is reported on the product label:
– Dabigatran—not recommended in patients who must
undergo anesthesia requiring the use of postoperative
permanent epidural catheters, as no information is
reported in the literature.
– Rivaroxaban—last administration 18 h before removal,
resume administration 6 h after removal; recent guide-
lines of the European Society of Anaesthesiology
suggest a longer period between last rivaroxaban dose
and epidural catheter removal (22–26 h) [10].
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See Table 5.
Management of vitamin K antagonist (VKA) patients
The main purpose is leading patients to surgical interven-
tion with an adequate hemostasis and reducing the risk of
thromboembolism as much as possible.
Femoral neck fracture (FNF) patients
Intervention should be delayed and INR measured: If INR[
2,administervitaminK10 mgin100 mlofsalineorglucose
solution i.v. and measure INR every 6/8 h until INR\2i s
attained. If INR \ 2, start LMWH administration at the
prophylactic dose and timing (4,000–5,000 IU/day), plan
surgical intervention as soon as possible, and request con-
sultation by a cardiologist and/or by an expert in hemostasis
and thrombosis to plan VKA resumption after surgery.
Patients candidate for elective hip (HR) and knee (KR)
replacement
Each hospital should have a written and shared protocol
concerning the management of VKA patients who have to
undergo major lower-limb orthopedic surgery; consultation
by a cardiologist and/or an expert in hemostasis and
thrombosis should be requested to prepare a personalized
schedule addressing VKA interruption and resumption; the
timing of surgery must be respected, and the procedure
should not be delayed.
Management of antiplatelet treatment (APT) patients
Aspirin administered as primary prevention must be
interrupted 7 days before elective surgery, whereas it must
be interrupted upon hospital admission in patients with
FNF planned for surgery. Aspirin administration as sec-
ondary prevention (in patients with prior cardiovascular
events) must be continued at the dose of 75–100 mg/day.
Femoral neck fracture (FNF) patients
For FNF, APT patients should undergo surgery as soon as
possible. For patients on clopidogrel or ticlopidine (or dual
anti-aggregation), request consultation by a cardiologist
and/or an expert in hemostasis and thrombosis.
Patients candidate for hip (HR) and knee (KR)
replacement
Administration of clopidogrel or ticlopidine must be
interrupted 7 and 10 days before surgery, respectively,
whereas in patients receiving dual anti-aggregation
(aspirin and clopidogrel), surgery must be delayed if
clopidogrel interruption is expected during the following
months; if interruption is not expected, request consul-
tation by a cardiologist and/or an expert in hemostasis
and thrombosis. In all such patients, as a general rule,
resume APT as soon as possible and regardless, once
hemostasis is achieved.
Patients at high risk of bleeding
In patients at high risk of bleeding, the absolute contrain-
dication to pharmacological prophylaxis is represented by
ongoing major bleeding. In this case, mechanical prophy-
laxis is indicated. The relative contraindication is applied
to all the other conditions for which patients are at high risk
of bleeding reported in Table 1. In these cases, pharma-
cological or transfusional correction of the hemostatic
defect is recommended whenever indicated and feasible,
considering mechanical and/or dedicated pharmacological
prophylaxis (dose reduction, postoperative initiation).
Table 5 Correlation between anesthesia and antiplatelet treatment (APT)
Regional anesthesia
a General anesthesia
Patients on APT with Patients on APT
Acetylsalicylic acid (ASA): do not interrupt
in case of secondary prevention (75–100 mg/day)
Ticlopidine—interrupt 10 days pre-op GA always feasible
IIb/IIIa inhibitors
Abciximab—RA contraindicated
Eptiﬁbatide—interrupt 8 h pre-op
Tiroﬁban—interrupt 4 h pre-op
Clopidogrel—interrupt 7 days pre-op Risk of surgical bleeding must always
be considered before surgery
a APT, if no bleeding occurs, must be resumed the day following the intervention and, in the presence of epidural catheterization, after catheter
removal
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Providing precise directives for managing such patients
goes beyond the purpose of this consensus statement; the
only indication is to pay extreme attention to them and to
request consultation by an expert on hemostasis and
thrombosis. Management of anticoagulant drugs in obese
patients [body mass index (BMI)[30] is not considered to
be different from what occurs with other patients. In
patients with renal failure, labels of the single drugs
administered must be referred to, and careful clinical
monitoring must follow.
General considerations
– Postoperative mobilization must be started as soon as
possible.
– Bed-rest patients should receive lower-limb mobiliza-
tion exercises.
– General practitioners and patients should be informed
how to recognize signs and symptoms of DVT and PE,
how to correctly manage home prophylaxis, and about
the risks of omitting it.
– Pharmaceutical companies and regulatory authorities
(Italian Medicines Agency, etc.) should keep labels
updated in agreement with scientiﬁc evidence reported
in the literature.
Conclusions
This document represents a consensus statement of Italian
experts, with information based on scientiﬁc knowledge
and labels available during the summer of 2010, and it will
be disseminated by the four societies via different modal-
ities (society journals, society Web sites, symposia orga-
nized within national congresses, etc.). A periodical
revision of this document is expected, which will be of
particular importance for the use of new anticoagulant
drugs currently undergoing clinical development, some of
which (edoxaban, betrixaban, and others) are still under-
going a preliminary trial phase. For other drugs (apixaban),
studies are already available [22, 23] that prove their efﬁ-
cacy and safety in VTE prevention in HR and KR surgery.
It is therefore likely that the number of drugs available for
this type of prophylaxis will increase in the near future.
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